Which Psychedelic Therapy Should Rural Health Systems Pursue First: Psilocybin or Ibogaine?

Rural health systems encounter disproportionate behavioral health burdens, including higher suicide rates, overdose mortality, poverty, and reduced access to specialty mental health and addiction care. As psychedelic-assisted therapies move toward possible clinical implementation, rural leaders may need to decide which therapies merit investment planning. This point–counterpoint compares psilocybin and ibogaine from a rural health system perspective rather than as a conventional pharmacologic review. Psilocybin currently has a more developed clinical evidence base, service delivery model, and regulatory pathway than ibogaine, although uncertainty remains regarding efficacy, approval, reimbursement, cost, and equitable access. Ibogaine may warrant additional research investment because it targets severe or treatment-refractory opioid use disorder, a smaller but high-risk population in many rural communities. However, its cardiac risks, limited evidence from controlled trials, and need for high-acuity monitoring make broad rural implementation premature. A phased approach may allow rural systems to focus on conditional psilocybin implementation planning while supporting carefully monitored ibogaine research partnerships.